An intranasal lentiviral booster broadens immune recognition of SARS-CoV-2 variants and reinforces the waning mRNA vaccine-induced immunity that it targets to lung mucosa

Running title: Boosting mRNA-induced SARS-CoV-2 immunity with a lentiviral-based nasal vaccine

Benjamin Vesin^{1,£}, Jodie Lopez^{1,£}, Amandine Noirat^{1,£}, Pierre Authié^{1,£}, Ingrid Fert¹, Fabien Le Chevalier¹, Fanny Moncoq¹, Kirill Nemirov¹, Catherine Blanc¹, Cyril Planchais², Hugo Mouquet², Françoise Guinet³, David Hardy⁴, Christiane Gerke⁵, François Anna¹, Maryline Bourguine¹, Laleh Majlessi^{1,§,*}, ✉, and Pierre Charneau^{1,§,*}

¹ Institut Pasteur-TheraVectys Joint Lab, Virology Department, 28 rue du Dr. Roux, Paris F-75015, France

² Laboratory of Humoral Immunology, Université de Paris, Immunology Department, Institut Pasteur, INSERM U1222, Paris F-75015, France

³ Lymphocytes and Immunity Unit, Université de Paris, Immunology Department, Institut Pasteur, Paris F-75015, France

⁴ Histopathology platform, Institut Pasteur, Paris F-75015, France

⁵ Institut Pasteur, Université de Paris, Innovation Office, Vaccine Programs, Institut Pasteur, Paris F-75015, France

[£]These authors contributed equally

[§]Senior authors

✉ Corresponding author: laleh.majlessi@pasteur.fr

Keywords

Intranasal Vaccination / Lentiviral Vaccine / SARS-CoV-2 Emerging Variants of Concern / Mucosal Immunity / Mucosal Booster Vaccine / Waning anti-COVID-19 Immunity

30 **Abstract**

31 As the COVID-19 pandemic continues and new SARS-CoV-2 variants of concern emerge, the
 32 adaptive immunity initially induced by the first-generation COVID-19 vaccines wains and needs to
 33 be strengthened and broadened in specificity. Vaccination by the nasal route induces mucosal
 34 humoral and cellular immunity at the entry point of SARS-CoV-2 into the host organism and has
 35 been shown to be the most effective for reducing viral transmission. The lentiviral vaccination
 36 vector (LV) is particularly suitable for this route of immunization because it is non-cytopathic, non-
 37 replicative and scarcely inflammatory. Here, to set up an optimized cross-protective intranasal
 38 booster against COVID-19, we generated an LV encoding stabilized Spike of SARS-CoV-2 Beta
 39 variant (LV::S_{Beta-2P}). mRNA vaccine-primed and -boosted mice, with waning primary humoral
 40 immunity at 4 months post-vaccination, were boosted intranasally with LV::S_{Beta-2P}. Strong boost
 41 effect was detected on cross-sero-neutralizing activity and systemic T-cell immunity. In addition,
 42 mucosal anti-Spike IgG and IgA, lung resident B cells, and effector memory and resident T cells
 43 were efficiently induced, correlating with complete pulmonary protection against the SARS-CoV-2
 44 Delta variant, demonstrating the suitability of the LV::S_{Beta-2P} vaccine candidate as an intranasal
 45 booster against COVID-19.

Introduction

Considering: (i) the sustained pandemicity of coronavirus disease 2019 (COVID-19), (ii) weakening protection potential of the first-generation vaccines against Severe Acute Respiratory Syndrome beta-coronavirus 2 (SARS-CoV-2), and (iii) ceaseless emergence of new viral Variants of Concerns (VOCs), new effective vaccine platforms can be critical for the future primary or booster vaccines [1]. We recently demonstrated the strong performance of a non-integrative lentiviral vaccination vector (LV) encoding the full-length sequence of Spike glycoprotein (S) from the ancestral SARS-CoV-2 (LV::S), when used in systemic prime followed by intranasal (i.n.) boost in multiple preclinical models [2]. LV::S ensures complete (cross) protection of the respiratory tract against ancestral SARS-CoV-2 and VOCs [3]. In addition, in our new transgenic mice expressing human Angiotensin Converting Enzyme 2 (hACE2) and displaying unprecedented permissiveness of the brain to SARS-CoV-2 replication, an i.n. boost with LV::S is required for full protection of the central nervous system [3]. LV::S is intended to be used as a booster for individuals who previously been vaccinated against and/or infected by SARS-CoV-2 to reinforce and broaden protection against emerging VOCs with immune evasion potential [4].

Vaccine LVs are non-integrating, non-replicative, non-cytopathic and negligibly inflammatory [5,6]. These vectors are pseudotyped with the heterologous glycoprotein from Vesicular Stomatitis Virus (VSV-G) which confers them a broad tropism for diverse cell types, including dendritic cells. The latter are mainly non-dividing cells and thus barely permissive to gene transfer. Hence, LVs possess the central property to efficiently transfer genes to the nuclei of not only dividing but also non-dividing cells, which therefore renders possible efficient transduction of non-dividing immature dendritic cells. The resulting endogenous antigen expression in these cells, with unique ability of dendritic cells to activate naïve T cells [7], correlate with a strong ability of LVs at inducing high-quality effector and memory T cells [8]. Importantly, VSV-G pseudo-typing also avoids LVs to be targets of preexisting vector-specific immunity in humans which is key in vaccine development [5,6]. The safety of LV has been established in humans in a phase I/IIa Human Immunodeficiency Virus-1 therapeutic vaccine trial, even though if an integrative version of LV had been used in that clinical trial [9]. Because of their non-cytopathic and non-inflammatory properties [10,11], LVs are well suitable for mucosal vaccination. The i.n. immunization approach is expected to trigger mucosal IgA responses, as well as resident B and T lymphocytes in the respiratory tract [12]. This immunization route has also been shown to be the most effective at reducing SARS-CoV-2 transmission in both hamster and macaque preclinical models [13]. Induction of mucosal immunity by i.n. immunization allows SARS-CoV-2 neutralization, directly at the gateway to the host organism, before it gains access to major infectable anatomical sites [2].

80 The duration of the protection conferred by the first generation COVID-19 vaccines is not yet
 81 well established, hardly predictable with serological laboratory tests and variable in diverse
 82 individuals and against distinct VOCs. Despite high vaccination rates, the current exacerbation of
 83 the world-wide pandemic indicates that repeated booster immunizations will be needed to ensure
 84 individual and collective immunity against COVID-19. In this context, the safety and potential
 85 adverse effects of multiple additional homologous doses of the first generation COVID-19 vaccines,
 86 for instance related to allergic reaction to polyethylene glycol (PEG) contained in mRNA vaccines,
 87 have to be taken into the account [14]. Importantly, an unmatched vaccine delivery method, i.e.,
 88 heterologous prime-boost format, has been proven to be a more successful strategy than
 89 homologous prime-boost approach in numerous preclinical models of various infectious diseases
 90 [15-17]. Therefore, new efficient vaccination platforms are of particular interest to develop
 91 heterologous boosters against COVID-19. The LV::S vaccine candidate has potential for
 92 prophylactic use against COVID-19, mainly based on its strong capacity to induce not only strong
 93 neutralizing humoral responses, but also and most importantly, robust protective T-cell responses
 94 which preserve their immune detection of spike from SARS-CoV-2 VOCs, despite the
 95 accumulation of escape mutations [3]. LV::S is remarkably suitable to be used, as a heterologous
 96 i.n. booster vaccine, to reinforce and broaden protection against the emerging VOCs, while
 97 collective immunity in early vaccinated nations is waning a few months after completion of the
 98 initial immunization, and while new waves of infections are on the rise [4].

99 In the present study, toward the preparation of a clinical trial, we first generated an LV encoding
 100 the down-selected S_{CoV-2} of the Beta variant, stabilized by K⁹⁸⁶P and V⁹⁸⁷P substitutions in the S2
 101 domain of S_{CoV-2} (LV::S_{Beta-2P}). In mice, primed and boosted intramuscularly (i.m.) with mRNA
 102 vaccine encoding for the ancestral S_{CoV-2} [18,19], and in which the (cross) sero-neutralization
 103 potential was progressively decreasing, we investigated the systemic and mucosal immune
 104 responses and the protective potential of an i.n. LV::S_{Beta-2P} heterologous boost.

Results

Antigen design and down-selection of a lead candidate

To select the most suitable S_{CoV-2} variant to induce the greatest neutralization breadth based on the known variants, we generated LVs encoding the full length S_{CoV-2} from the Alpha, Beta or Gamma SARS-CoV-2 VOCs. C57BL/6 mice ($n = 5/\text{group}$) were primed i.m. (wk 0) and boosted i.m. (wk 3) with 1×10^8 TU/mouse of each individual LV and the (cross) neutralization potential of their sera was assessed before boost (wk 3) and after boost (wk 5) against pseudoviruses carrying various S_{CoV-2} (**Figure 1A**). Immunization with LV::S_{Alpha} generated appropriate neutralization capacity against S_{D614G} and S_{Alpha} but not against S_{Beta} and S_{Gamma} (**Figure 1B**). Between LV::S_{Beta} and LV::S_{Gamma}, the former generated the highest cross sero-neutralization potential against S_{D614G}, S_{Alpha} and S_{Gamma} variants. In accordance with previous observations using other vaccination strategies, in the context of immunization with LV, the K⁹⁸⁶P - V⁹⁸⁷P substitutions in the S2 domain of S_{CoV-2} improved the (cross) sero-neutralization potential (**Figure 1C**), probably due to an extended half-life of S_{CoV-2-2P} [20].

Taken together these data allowed to down select S_{Beta-2P} as the best cross-reactive antigen candidate to be used in the context of LV (LV::S_{Beta-2P}) to strengthen the waning immunity previously induced by the first generation COVID-19 vaccines, like mRNA.

Follow-up of humoral immunity in mRNA-primed and -boosted mice and effect of LV::S_{Beta-2P} i.n. boost

We analyzed the potential of LV::S_{Beta-2P} i.n. boost vaccination to strengthen and broaden the immune responses in mice which were initially primed and boosted with mRNA and in which the (cross) sero-neutralization potential was decreasing. C57BL/6 mice were primed i.m. at wk 0 and boosted i.m. at wk 3 with 1 µg/mouse of mRNA (**Figure 2A**). In mRNA-primed mice, serum anti-S_{CoV-2} and anti-RBD IgG were detected at wk 3, increased after mRNA boost as studied at wk 6 and 10, and then decreased at wk 17 in the absence of an additional boost (**Figure S1A**).

Longitudinal serological follow-up demonstrated that at 3 wks post prime, cross-neutralization activities against both S_{D614G} and S_{Alpha} were readily detectable (**Figure 2B**). Cross sero-neutralization was also detectable, although to a lesser degree, against S_{Gamma}, but not against S_{Beta}, S_{Delta} or S_{Delta+}. At wk 6, i.e., 3 wks post boost, cross sero-neutralization activities against all S_{CoV-2} variants were detectable, although at significantly lesser extents against S_{Beta}, S_{Delta} and S_{Delta+}. From wk 6 to wk 10, cross sero-neutralization against S_{Beta}, S_{Delta}, or S_{Delta+} gradually and

significantly decreased. At wk 10, half of the mice lost the cross sero-neutralization potential against S_{Beta} , S_{Delta} , or $S_{\text{Delta+}}$ (Figure 2B).

At wk 15, groups of mRNA-primed and -boosted mice received i.n. escalating doses of 1×10^6 , 1×10^7 , 1×10^8 , or 1×10^9 Transduction Units (TU)/mouse of LV:: $S_{\text{Beta-2P}}$ (Figure 2A). Control mRNA-primed and -boosted mice received i.n. 1×10^9 TU of an empty LV (LV Ctrl). In parallel, at this time point, mRNA-primed and -boosted mice were injected i.m. with 1 μg of mRNA-vaccine or PBS. The dose of 1 μg of mRNA per mouse has been demonstrated to be fully protective in mice [21]. Unprimed, age-matched mice received i.n. 1×10^9 TU of LV:: $S_{\text{Beta-2P}}$ or PBS.

In the previously mRNA-primed and -boosted mice, injected at wk 15 with 1×10^8 or 1×10^9 TU of LV:: $S_{\text{Beta-2P}}$ or a third dose of mRNA, marked anti- $S_{\text{CoV-2}}$ IgG titer increases were observed (Figure 2C). The titers of anti- $S_{\text{CoV-2}}$ IgA were higher in the mice injected with 1×10^9 TU of LV:: $S_{\text{Beta-2P}}$ than those injected with a third 1 μg dose of mRNA vaccine (Figure 2C). At the mucosal level, at this time point, titers of anti- $S_{\text{CoV-2}}$ and anti-RBD IgG in the total lung extracts increased in a dose-dependent manner in LV:: $S_{\text{Beta-2P}}$ -boosted mice, and the titer obtained with the highest dose of LV:: $S_{\text{Beta-2P}}$ was comparable to that after the third 1 μg i.m. dose of mRNA vaccine (Figure S1B). Importantly, significant titers of lung anti- $S_{\text{CoV-2}}$ IgA were only detected in LV:: $S_{\text{Beta-2P}}$ -boosted mice (Figure S1B).

At the lung cellular level, CD19^+ B cells which are class-switched and thus surface IgM/IgD⁺ plasma cells, and which express CD38, CD62L, CD73 and CD80, can be defined as lung resident B cells (Brm) [22,23] (Figure 3A). The proportion of these B cells increased in a dose-dependent manner in the lungs of mice boosted i.n. with LV:: $S_{\text{Beta-2P}}$ (Figure 3B). Mucosal anti- $S_{\text{CoV-2}}$ IgA and Brm were barely detectable in the mice boosted i.m. at wk15 with 1 μg of mRNA, which was the single dose of RNA tested in our experiment and thus serves only as indication.

Systemic and mucosal T-cell immunity after i.n. LV:: $S_{\text{Beta-2P}}$ boost in previously mRNA-primed and -boosted mice

Mice were primed and boosted with 1 μg mRNA-vaccine and then boosted i.n. at wk15 with escalating doses of LV:: $S_{\text{Beta-2P}}$, according to the above-mentioned regimen (Figure 2A). At wk 17, i.e., two wks after the late boost, systemic anti- $S_{\text{CoV-2}}$ T-cell immunity was assessed by IFN- γ -specific ELISPOT in the spleen of individual mice after in vitro stimulation with individual S:256-275, S:536-550 or S:576-590 peptide, encompassing immunodominant $S_{\text{CoV-2}}$ regions for CD8^+ T cells in H-2^b mice [2]. Importantly, the weak anti-S CD8^+ T-cell immunity, detectable in the

spleen of mRNA-primed-boosted mice at wk 17, largely increased following i.n. boost with 1×10^8 and 1×10^9 TU of LV::S_{Beta-2P}, similarly to the increase after i.m. mRNA boost (Figure 4).

In parallel, in the same animals, the mucosal anti-S_{CoV-2} T-cell immunity was assessed by intracellular Tc1 and Tc2 cytokine staining in T cell-enriched fraction from individual mice after in vitro stimulation with autologous bone-marrow-dendritic cells loaded with a pool of S:256-275, S:536-550 and S:576-590 peptides (Figure 5). In previously mRNA-primed and -boosted mice, only a few S_{CoV-2}-specific IFN- γ /TNF/IL-2 CD8⁺ T-cell responses were detected in the lungs (Figure 5). The i.n. administration of LV::S_{Beta-2P} boosted, in a dose dependent manner, these Tc1 responses. Sizable percentages of these Tc1 cells were induced with 1×10^8 or 1×10^9 TU of LV::S_{Beta-2P}. mRNA (1 μ g) i.m. administration had a substantially lower boost effect on mucosal T cells (Figure 5). Tc2 responses (IL-4, IL-5, IL-10 and IL-13) were not detected in any experimental group (Figure S2), as assessed in the same lung T-cell cultures.

Mucosal lung resident memory T cells (Trm), CD8⁺ CD44⁺ CD69⁺ CD103⁺ which are one of the best correlates of protection in the infectious diseases [24], were readily detected in the mice boosted i.n. with 1×10^8 or 1×10^9 TU of LV::S_{Beta-2P} (Figure 6A, B). No Trm were detected in the lungs of mice boosted late with 1 μ g mRNA i.m..

Features of lungs after LV::S_{Beta-2P} i.n. administration

To identify the immune cell subsets transduced in vivo by LV after i.n. administration, C57BL/6 mice were immunized i.n. with the high dose of 1×10^9 TU of LV::GFP or LV::nano-Luciferase (LV::nLuc) as a negative control. Lungs were collected at 4 days post-immunization and analyzed by cytometry in individual mice. CD45⁺ cell subset was devoid of GFP⁺ cells. Only a very few GFP⁺ cells were detected in the CD45⁺ hematopoietic cells (Figure S3A-C). The CD45⁺ GFP⁺ cells were located in a CD11b^{hi} subset and in the CD11b^{int} CD11c⁺ CD103⁺ MHC-II⁺ (dendritic cells) (Figure S3B).

To evaluate possible lung infiltration after LV i.n. administration, C57BL/6 mice were injected i.n. with the high dose of 1×10^9 TU of LV::S_{Beta-2P} or PBS as a negative control. Lungs were collected at 1, 3 or 14 days post-injection for histopathological analysis. H&E histological sections displayed minimal to moderate inflammation, interstitial and alveolar syndromes in both experimental groups, regardless of the three time points investigated. No specific immune infiltration or syndrome was detected in the animals treated i.n. with 1×10^9 TU of LV::S_{Beta-2P}, compared to PBS (Figure S4A, B).

Protection of lungs in mRNA-primed and -boosted mice, and later boosted i.n. with LV::S_{Beta-2P}

We then evaluated the protective vaccine efficacy of LV::S_{Beta-2P} i.n. in mRNA-primed and -boosted mice. At wk 15, mRNA-primed and -boosted mice received i.n. 1×10^8 TU of LV::S_{Beta-2P} or control empty LV. (Figure 7A). The choice of this dose was based on our previous experience with this dose which was effective in protection in homologous LV::S prime-boost regimens [2,3]. Control mRNA-immunized mice received i.m. 1 µg of mRNA or PBS. Unvaccinated, age-and sex-matched controls were left unimmunized. Five weeks after the late boost, i.e. at wk 20, all mice were pre-treated with 3×10^8 Infectious Genome Units (IGU) of an adenoviral vector serotype 5 encoding hACE2 (Ad5::hACE2) [2] to render their lungs permissive to SARS-CoV-2 replication (Figure 7A). Four days later, mice were challenged with SARS-CoV-2 Delta variant, which at the time of this study, i.e. November 2021, was the dominant SARS-CoV-2 variant worldwide.

At day 3 post infection, primary analysis of the total lung RNA showed that hACE2 mRNA was similarly expressed in all mice after Ad5::hACE2 *in vivo* transduction (Figure 7B). Lung viral loads were then determined at 3 dpi by assessing total E RNA and sub-genomic (Esg) E_{CoV-2} RNA qRT-PCR, the latter being an indicator of active viral replication [25-27]. In mice initially primed and boosted with mRNA-vaccine and then injected i.n. with the control LV or i.m. with PBS, no significant protective capacity was detectable (Figure 7C). In contrast, the LV::S_{Beta-2P} i.n. boost of the initially mRNA vaccinated mice drastically reduced the total E RNA content of SARS-CoV-2 and no copies of the replication-related Esg E_{CoV-2} RNA were detected in this group (Figure 7C). In the group which received a late mRNA i.m. boost, the total E RNA content was also significantly reduced and the content of Esg E_{CoV-2} RNA was undetectable in 3 out of 5 in this group.

Therefore, a late LV::S_{Beta-2P} heterologous i.n. boost, given at wk 15 after the first injection of mRNA, at the dose of 1×10^8 TU/mouse resulted in complete protection, i.e. total absence of viral replication in 100% of animals, against a high dose challenge with SARS-CoV-2 Delta variant.

Discussion

With the weakly persistent prophylactic potential of the immunity initially induced by the first-generation COVID-19 vaccines, especially against new VOCs, administration of additional vaccine doses becomes essential [1]. As an alternative to additional doses of the same vaccines, combining vaccine platforms in a heterologous prime-boost regimen holds promise for gaining protective efficacy [28]. Compared to homologous vaccine dose administrations, heterologous prime-boost strategies may reinforce more efficiently specific adaptive immune responses and long-term protection [29]. Furthermore, the sequence of the Spike antigen has to be adapted according to the dynamics of SARS-CoV-2 VOC emergence in order to induce the greatest neutralization breadth. Protection against symptomatic SARS-CoV-2 infection is mainly related to sero-neutralizing activity, while CD8⁺ T-cell immunity, with their ability to cytolyze virus-infected cells, especially control the virus replication and result in resolution of viral infection [30]. Therefore, an appropriate B- and T-cell vaccine platform, including an adapted S_{CoV2} sequence, is of utmost interest at the current step of the pandemic.

The LV-based strategy, which is highly efficient, not only in inducing humoral responses but also, and particularly, in establishing high quality and memory T-cell responses [8], is a favorable platform for a heterologous boost, even if it is also largely efficacious by its own as a primary COVID-19 vaccine candidate [2,3]. Furthermore, LV is non-cytopathic, non-replicative and scarcely inflammatory and thus can be used to perform non-invasive i.n. boost to efficiently induce sterilizing mucosal immunity, which protects the respiratory system as well as the central nervous system [2,3]. The i.n. route of vaccination has been shown by several teams to be the most efficacious route at reducing viral contents in nasal swabs and nasal olfactory neuroepithelium [31,32], which can contribute to block the respiratory chain of SARS-CoV-2 transmission. One of the advantages of LV-based immunization is the induction of strong T-cell immune responses with high cross-reactivity of T-cell epitopes from Spike of diverse VOCs. Therefore, when the neutralizing antibody fails or wanes, the T-cell arm remains largely protective, as we recently described in antibody-deficient, B-cell compromised μ MT KO mice [3]. This property is relative to a high-quality and long-lasting T-cell immunity induced against multiple preserved T-cell epitopes, despite the mutations accumulated in the Spike of the emerging VOCs [3], including the Omicron variant.

In the present study, we down-selected the S_{Beta-2P} antigen which induced the greatest neutralization breadth against the main SARS-CoV-2 VOCs and designed a non-integrative LV encoding a stabilized version of this antigen. In mice primed and boosted with mRNA vaccine (encoding the ancestral S_{CoV-2} sequence), with waning (cross) sero-neutralization capacity, we used

escalating doses of LV::S_{Beta-2P} for an i.n. late boost. We demonstrated a dose-dependent increase in anti-S_{CoV-2} IgG and IgA titers, and a broadened sero-neutralization potential both in the sera and lung homogenates against VOCs. No anti-S_{CoV-2} IgA was detected in the lungs of mice injected with the third dose of 1 µg of mRNA given via i.m.. Increasing proportions of non-circulating Brm, defined as class-switched surface IgM⁺/IgD⁺ plasma cells, with CD38⁺ CD73⁺ CD62L⁺ CD69⁺ CD80⁺ phenotype [22,23], were detected in a dose-dependent manner, in the lungs of mice boosted i.n. with LV::S_{Beta-2P}.

Spike-specific, effector lung CD8⁺ Tc1 cells were largely detected in the initially mRNA-primed and boosted mice which received a late i.n. LV::S_{Beta-2P} boost. These lung CD8⁺ T cells did not display Tc2 phenotype. Increasing proportions of lung CD8⁺ CD44⁺ CD69⁺ CD103⁺ Trm were also detected, in a dose-dependent manner, only in LV::S_{Beta-2P} i.n. boosted mice. The systemic CD8⁺ T-cell responses against various immunogenic regions of S_{CoV-2} were also increased with 1×10^8 or 1×10^9 TU doses of LV::S_{Beta-2P} i.n. boost in the initially mRNA-primed and -boosted mice. The highest i.n. dose of LV::S_{Beta-2P} was comparable to the third injection of 1 µg/mouse of mRNA given by i.m.. The fact that the i.n. administration of LV::S_{Beta-2P} had a substantial boost effect on the systemic T-cell immunity indicates that this boost pathway is not at the expense of the induction of systemic immunity. Evaluation of the protection in mRNA-primed and -boosted mice, showed that 20 wk after the first injection of mRNA vaccine, there was no protection detectable in the lungs against infection with the SARS-CoV-2 Delta variant. Importantly, an i.n. boost at wk 15 with the dose of 1×10^8 TU/mouse LV::S_{Beta-2P} resulted in full inhibition of SARS-CoV-2 replication in the lungs upon challenge with the Delta variant at wk 20. In the mice receiving an 1 µg mRNA i.m. boost at wk 15 the lung SARS-CoV-2 RNA contents was reduced in a statistically comparable manner, albeit without total inhibition of viral replication in all mice.

The lack of protection against the Delta variant infection only four months after the initial systemic prime-boost by mRNA vaccine, as we observed in the preclinical model in this study, may be explained by the weak efficiency of the ancestral S_{CoV-2} sequence to induce long-lasting neutralizing antibodies against the recent VOCs. In addition, it can be hypothesized that the adaptive immune memory induced by i.m. mRNA immunization is likely to be localized in secondary lymphoid organs at anatomical sites located far from the upper respiratory tract. In such a context, the extraordinary rapid replication of new VOCs, such as Delta or Omicron, in the upper respiratory tract would not leave enough time for the reactivation of immune memory from remote anatomical sites and the recruitment of the immune arsenal from these sites. In human populations, such scenario would lead to a high possibility of viral replication and variable levels of its

transmission, which would prevent the epidemic from being completely contained by mass vaccination through the systemic route.

It is not yet known if a single third booster will extend and maintain the protective potential, or whether semi-regular boosters will be required against COVID-19 in the future. The LV::S_{Beta-2P} i.n. boost strengthens the intensity, broadens the VOC cross-recognition, and targets B- and T-cell immune responses to the principal entry point of SARS-CoV-2 to the mucosal respiratory tract of the host organism and avoid the infection of main anatomical sites. It is interesting to note that in rodents only a pair of cervical ganglia exists versus a large network of such ganglia in humans [33]. Following i.n. immunization, this anatomical feature in humans may provide even a more consistent site of immune response induction and local memory maintenance, at the vicinity of to the potential site of airway infection. In addition, nasopharynx-associated lymphoid tissue is a powerful defense system composed of: (i) organized lymphoid tissue, i.e., tonsils, and (ii) a diffuse nose-associated lymphoid tissues, where effector and memory B and T lymphocytes are able to maintain long-lasting immunity [34]. This mucosal immune arsenal deserves to be explored in the control of SARS-CoV-2 transmission in the current context of the pandemic. A phase I clinical trial is currently in preparation for the use of i.n. boost by LV::S_{Beta-2P} in previously vaccinated humans or in COVID-19 convalescents.

Materials and Methods

Mice immunization and SARS-CoV-2 infection

Female C57BL/6J mice were purchased from Janvier (Le Genest Saint Isle, France), housed in individually-ventilated cages under specific pathogen-free conditions at the Institut Pasteur animal facilities and used at the age of 7 wks. Mice were immunized i.m. with 1 µg/mouse of mRNA-1273 (Moderna) vaccine. For i.n. injections with LV, mice were anesthetized by i.p. injection of Ketamine (Imalgene, 80 mg/kg) and Xylazine (Rompun, 5 mg/kg). For protection experiments against SARS-CoV-2, mice were transferred into filtered cages in isolator. Four days before SARS-CoV-2 inoculation, mice were pretreated with 3×10^8 IGU of Ad5::hACE2 as previously described [2]. Mice were then transferred into a level 3 biosafety cabinet and inoculated i.n. with 0.3×10^5 TCID₅₀ of the Delta variant of SARS-CoV-2 clinical isolate [35] contained in 20 µl. Mice were then housed in filtered cages in an isolator in BioSafety Level 3 animal facilities. The organs recovered from the infected animals were manipulated according to the approved standard procedures of these facilities.

Ethical approval of animal experimentation

Experimentation on animals was performed in accordance with the European and French guidelines (Directive 86/609/CEE and Decree 87-848 of 19 October 1987) subsequent to approval by the Institut Pasteur Safety, Animal Care and Use Committee, protocol agreement delivered by local ethical committee (CETEA #DAP20007, CETEA #DAP200058) and Ministry of High Education and Research APAFIS#24627-2020031117362508 v1, APAFIS#28755-2020122110238379 v1.

Construction and production of vaccinal LV::S_{Beta-2P}

First, a codon-optimized sequence of Spike from the Ancestral, D614G, Alpha, Beta or Gamma VOCs were synthesized and inserted into the pMK-RQ_S-2019-nCoV_S501YV2 plasmid. The S sequence was then extracted by BamHI/XhoI digestion to be ligated into the pFlap lentiviral plasmid between the BamHI and XhoI restriction sites, located between the native human ieCMV promoter and the mutated *atg* starting codon of Woodchuck Posttranscriptional Regulatory Element (WPRES) sequence (Figure S5). To introduce the K⁹⁸⁶P-V⁹⁸⁷P “2P” double mutation in S_{D614G} or S_{Beta}, a directed mutagenesis was performed by use of Takara In-Fusion kit on the corresponding pFlap plasmids. Various pFlap-ieCMV-S-WPREm or pFlap-ieCMV-S_{2P}-WPREm plasmids were amplified and used to produce non-integrative vaccinal LV, as described elsewhere [2,6].

Analysis of humoral and systemic T-cell immunity

Anti-S_{CoV-2} IgG and IgA antibody titers were determined by ELISA by use of recombinant stabilized S_{CoV-2} or RBD fragment for coating. Neutralization potential of clarified and decompartmented sera or lung homogenates was quantitated by use of lentiviral particles pseudotyped with S_{CoV-2} from diverse variants, as previously described [2,36].

T-splenocyte responses were quantitated by IFN- γ ELISPOT after in vitro stimulation with S:256-275, S:536-550 or S:576-590 synthetic 15-mer peptides which contain S_{CoV-2} MHC-I-restricted epitopes in H-2^d mice [2]. Spots were quantified in a CTL Immunospot S6 ultimate-V Analyser by use of CTL Immunocapture 7.0.8.1 program.

Phenotypic and Functional cytometric analysis of lung immune cells

Enrichment and staining of lung immune cells were performed as detailed elsewhere [2,3] after treatment with 400 U/ml type IV collagenase and DNase I (Roche) for a 30-minute incubation at 37°C and homogenization by use of GentleMacs (Miltenyi Biotec). Cell suspensions were then filtered through 100 μ m-pore filters, centrifuged at 1200 rpm and enriched on Ficoll gradient after 20 min centrifugation at 3000 rpm at RT, without brakes. The recovered cells were co-cultured with syngeneic bone-marrow derived dendritic cells loaded with a pool of A, B, C peptides, each at 1 μ g/ml or negative control peptide at x μ g/ml. The following mixture was used to detect lung Tc1 cells: PerCP-Cy5.5-anti-CD3 (45-0031-82, eBioScience), eF450-anti-CD4 (48-0042-82, eBioScience) and APC-anti-CD8 (17-0081-82, eBioScience) for surface staining and BV650-anti-IFN- γ (563854, BD), FITC-anti-TNF (554418, BD) and PE-anti-IL-2 (561061, BD) for intracellular staining. The following mixture was used to detect lung Tc2 cells: PerCP-Cy5.5-anti-CD3 (45-0031-82, eBioScience), eF450-anti-CD4 (48-0042-82, eBioScience), BV711-anti-CD8 (563046, BD Biosciences), for surface staining and BV605-anti-IL-4 (504125, BioLegend Europe BV), APC-anti-IL-5 (504306, BioLegend Europe BV), FITC-anti-IL-10 (505006, BioLegend Europe BV), PE-anti-IL-13 (12-7133-81, eBioScience) for intracellular staining. The intracellular staining was performed by use of the Fix Perm kit (BD), following the manufacturer's protocol. Dead cells were excluded by use of Near IR Live/Dead (Invitrogen). Staining was performed in the presence of Fc γ II/III receptor blocking anti-CD16/CD32 (BD).

To identify lung resident memory CD8⁺ T-cell subsets, a mixture of PerCP-Vio700-anti-CD3 (130-119-656, Miltenyi Biotec), PECy7-CD4 (552775, BD Biosciences), BV510-anti-CD8 (100752, BioLegend), PE-anti-CD62L (553151, BD Biosciences), APC-anti-CD69 (560689, BD Biosciences), APC-Cy7-anti-CD44 (560568, BD Biosciences), FITC-anti-CD103 (11-1031-82, eBiosciences) and yellow Live/Dead (Invitrogen) was used. Lung Brm were studied by surface staining with a mixture of PerCP Vio700-anti-IgM (130-106-012, Miltenyi), and PerCP Vio700-anti-IgD (130-103-797, Miltenyi), APC-H7-anti-CD19 (560143, BD Biosciences), PE-anti-CD38

(102708, BioLegend Europe BV), PE-Cy7-anti-CD62L (ab25569, AbCam), BV711-anti-CD69 (740664, BD Biosciences), BV421-anti-CD73 (127217, BioLegend Europe BV), FITC-anti-CD80 (104705, BioLegend Europe BV and yellow Live/Dead (Invitrogen).

Cells were incubated with appropriate mixtures for 25 minutes at 4°C, washed in PBS containing 3% FCS and fixed with Paraformaldehyde 4% after an overnight incubation at 4°C. Samples were acquired in an Attune NxT cytometer (Invitrogen) and data analyzed by FlowJo software (Treestar, OR, USA).

Determination of viral RNA content in the organs

Organs from mice were removed and immediately frozen at -80°C on dry ice. RNA from circulating SARS-CoV-2 was prepared from lungs as described elsewhere [2]. Lung homogenates were prepared by thawing and homogenizing in lysing matrix M (MP Biomedical) with 500 µl of PBS using a MP Biomedical Fastprep 24 Tissue Homogenizer. RNA was extracted from the supernatants of organ homogenates centrifuged during 10 min at 2000g, using the Qiagen Rneasy kit, except that the neutralization step with AVL buffer/carrier RNA was omitted. The RNA samples were then used to determine viral RNA content by E-specific qRT-PCR. To determine viral RNA content by Esg-specific qRT-PCR, total RNA was prepared using lysing matrix D (MP Biomedical) containing 1 mL of TRIzol reagent (ThermoFisher) and homogenization at 30 s at 6.0 m/s twice using MP Biomedical Fastprep 24 Tissue Homogenizer. The quality of RNA samples was assessed by use of a Bioanalyzer 2100 (Agilent Technologies). Viral RNA contents were quantitated using a NanoDrop Spectrophotometer (Thermo Scientific NanoDrop). The RNA Integrity Number (RIN) was 7.5-10.0. SARS-CoV-2 E or E sub-genomic mRNA were quantitated following reverse transcription and real-time quantitative TaqMan® PCR, using SuperScript™ III Platinum One-Step qRT-PCR System (Invitrogen) and specific primers and probe (Eurofins), as recently described [3].

Lung histology

Left lobes from lungs were fixed in formalin and embedded in paraffin. Paraffin sections (5-µm thick) were stained with Hematoxylin and Eosin (H&E). Slides were scanned using the AxioScan Z1 (Zeiss) system and images were analyzed with the Zen 2.6 software. Histological images were evaluated according to a score of 0 to 5 (normal, minimal, mild, moderate, marked, severe).

References

1. https://cdn.who.int/media/docs/default-source/immunization/sage/covid/global-covid-19-vaccination-strategic-vision-for-2022_sage-yellow-book.pdf?sfvrsn=4827ec0d_5. (2021).
2. Ku MW, Bourguine M, Authie P *et al*. Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models. *Cell Host Microbe*, 29(2), 236-249 e236 (2021).
3. Ku MW, Authie P, Bourguine M *et al*. Brain cross-protection against SARS-CoV-2 variants by a lentiviral vaccine in new transgenic mice. *EMBO Mol Med*, e14459 (2021).
4. Juno JA, Wheatley AK. Boosting immunity to COVID-19 vaccines. *Nat Med*, 27(11), 1874-1875 (2021).
5. Hu B, Tai A, Wang P. Immunization delivered by lentiviral vectors for cancer and infectious diseases. *Immunol Rev*, 239(1), 45-61 (2011).
6. Ku MW, Charneau P, Majlessi L. Use of lentiviral vectors in vaccination. *Expert Rev Vaccines*, 1-16 (2021).
7. Guernonprez P, Gerber-Ferder Y, Vaivode K, Bourdely P, Helft J. Origin and development of classical dendritic cells. *Int Rev Cell Mol Biol*, 349, 1-54 (2019).
8. Ku MW, Authie P, Nevo F *et al*. Lentiviral vector induces high-quality memory T cells via dendritic cells transduction. *Commun Biol*, 4(1), 713 (2021).
9. TheraVectys-Clinical-Trial. Safety, Tolerability and Immunogenicity Induced by the THV01 Treatment in Patients Infected With HIV-1 Clade B and Treated With Highly Active Antiretroviral Therapy (HAART). <https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006260-52>, 2011-006260-52 (2019).
10. Cousin C, Oberkamp M, Felix T *et al*. Persistence of Integrase-Deficient Lentiviral Vectors Correlates with the Induction of STING-Independent CD8(+) T Cell Responses. *Cell Rep*, 26(5), 1242-1257 e1247 (2019).
11. Lopez J, Anna F, Authie P *et al*. An optimized lentiviral vector induces CD4+ T-cell immunity and predicts a booster vaccine against tuberculosis. *Submitted*.
12. Lund FE, Randall TD. Scent of a vaccine. *Science*, 373(6553), 397-399 (2021).
13. van Doremalen N, Purushotham JN, Schulz JE *et al*. Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models. *Sci Transl Med*, 13(607) (2021).
14. Castells MC, Phillips EJ. Maintaining Safety with SARS-CoV-2 Vaccines. *N Engl J Med*, 384(7), 643-649 (2021).
15. He Q, Mao Q, An C *et al*. Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates. *Emerg Microbes Infect*, 10(1), 629-637 (2021).
16. Lu S. Heterologous prime-boost vaccination. *Curr Opin Immunol*, 21(3), 346-351 (2009).
17. Nordstrom P, Ballin M, Nordstrom A. Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study. *Lancet Reg Health Eur*, 100249 (2021).
18. Jackson LA, Anderson EJ, Roupheal NG *et al*. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. *N Engl J Med*, 383(20), 1920-1931 (2020).
19. Wang F, Kream RM, Stefano GB. An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development. *Med Sci Monit*, 26, e924700 (2020).
20. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. *Cell*, 181(2), 281-292 e286 (2020).
21. Corbett KS, Edwards DK, Leist SR *et al*. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. *Nature*, 586(7830), 567-571 (2020).
22. Barker KA, Etesami NS, Shenoy AT *et al*. Lung-resident memory B cells protect against bacterial pneumonia. *J Clin Invest*, 131(11) (2021).
23. Onodera T, Takahashi Y, Yokoi Y *et al*. Memory B cells in the lung participate in protective humoral immune responses to pulmonary influenza virus reinfection. *Proc Natl Acad Sci U S A*, 109(7), 2485-2490 (2012).
24. Masopust D, Soerens AG. Tissue-Resident T Cells and Other Resident Leukocytes. *Annu Rev Immunol*, 37, 521-546 (2019).
25. Chandrashekar A, Liu J, Martinot AJ *et al*. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. *Science*, 369(6505), 812-817 (2020).
26. Tostanoski LH, Wegmann F, Martinot AJ *et al*. Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters. *Nat Med*, 26(11), 1694-1700 (2020).
27. Wolfel R, Corman VM, Guggemos W *et al*. Virological assessment of hospitalized patients with COVID-2019. *Nature*, 581(7809), 465-469 (2020).
28. Barros-Martins J, Hammerschmidt SI, Cossmann A *et al*. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. *Nat Med*, 27(9), 1525-1529 (2021).
29. Kardani K, Bolhassani A, Shahbazi S. Prime-boost vaccine strategy against viral infections: Mechanisms and benefits. *Vaccine*, 34(4), 413-423 (2016).
30. Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. *Cell*, 184(4), 861-880 (2021).

31. Bricker TL, Darling TL, Hassan AO *et al.* A single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters. *Cell Rep*, 36(3), 109400 (2021).
32. Hassan AO, Feldmann F, Zhao H *et al.* A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques. *Cell Rep Med*, 2(4), 100230 (2021).
33. <https://teachmeanatomy.info/neck/vessels/lymphatics/>.
34. Porzia A, Cavaliere C, Begvarfaj E, Masieri S, Mainiero F. Human nasal immune system: a special site for immune response establishment. *J Biol Regul Homeost Agents*, 32(1 Suppl. 1), 3-8 (2018).
35. Planas D, Veyer D, Baidaliuk A *et al.* Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. *Nature*, 596(7871), 276-280 (2021).
36. Sterlin D, Mathian A, Miyara M *et al.* IgA dominates the early neutralizing antibody response to SARS-CoV-2. *Sci Transl Med*, 13(577) (2021).

Acknowledgments

The authors are grateful to Dr. Marie José Quentin-Millet and Estelle Besson (TheraVectys) for precious discussion and advices, and to Magali Tichit et Sabine Maurin for excellent technical assistance in preparing histological sections. The SARS-CoV2 variant Delta/2021/I7.2 200 was supplied by the Virus and Immunity Unit (Institut Pasteur, Paris, France) headed by Olivier Schwartz.

This work was supported by TheraVectys and Institut Pasteur.

Author Contributions

Study concept and design: BV, JL, CG, MB, LM, PC, acquisition of data: BV, JL, AN, PA, IF, FLC, FM, KN, MB, LM, construction and production of LV and technical support: AN, FM, CB, FA, histology: FG, DH, recombinant Spike protein: CP, HM, analysis and interpretation of data: BV, JL, FA, MB, LM, PC, drafting of the manuscript: LM.

Conflict of Interests

PC is the founder and CSO of TheraVectys. BV, AN, PA, IF, FLC, FM, KN and FA are employees of TheraVectys. LM has a consultancy activity for TheraVectys. Other authors declare no competing interests. PA, IF, JL, BV, FA, MB, LM and PC are inventors of pending patents directed to the potential of i.n. LV::S vaccination against SARS-CoV-2.

Figure 1

Figure 1. Down-selection of a S_{CoV-2} variant with the highest potential to induce cross sero-neutralizing antibodies. (A) Timeline of prime-boost vaccination with LV::S_{Alpha}, LV::S_{Beta} or LV::S_{Gamma} and (cross) sero-neutralization assays in C57BL/6 mice ($n = 4-5/\text{group}$). (B) EC₅₀ of neutralizing activity of sera from vaccinated mice was evaluated before and after the boost, against pseudo-viruses carrying S_{CoV-2} from D614G, Alpha, Beta or Gamma variants. (C) EC₅₀ of sera from C57BL/6 mice, vaccinated following the regimen detailed in (A) with LV encoding for S_{D614G}, either WT or carrying the K⁹⁸⁶P - V⁹⁸⁷P substitutions in the S2 domain. EC₅₀ was evaluated before and after the boost, as indicated in (B).

Figure 2. Anti-S_{CoV-2} humoral responses in mRNA-vaccinated mice which were further intranasally boosted with LV::S_{Beta-2P} (A) Timeline of mRNA i.m.-i.m. prime-boost vaccination in C57BL/6 mice which were later immunized i.n. by escalating doses of LV::S_{Beta-2P} ($n = 4-5$ /group) and the (cross) sero-neutralization follow-up. (B) Serum EC50 determined at the indicated time points against pseudo-viruses carrying S_{CoV-2} from D614G, Alpha, Beta, Gamma, Delta or Delta+ variants. (C) Anti-S_{CoV-2} IgG (upper panel) or IgA (lower panel) titers in the sera two weeks after i.n. LV::S_{Beta-2P} boost. Statistical significance was determined by Mann-Whitney test (*= $p < 0.05$, **= $p < 0.01$, ***= $p < 0.001$).

Figure 3

Figure 4

Figure 4. Systemic CD8⁺ T-cell responses to SCoV-2 in mRNA-vaccinated mice which were further intranasally boosted with LV::SBeta-2P. The mice are those detailed in the Figure 2. T-splenocyte responses were evaluated two weeks after LV::SBeta-2P i.n. boost by IFN- γ ELISPOT after stimulation with S:256-275, S:536-550 or S:576-590 synthetic 15-mer peptides encompassing SCoV-2 MHC-I-restricted epitopes. Statistical significance was evaluated by Mann-Whitney test (*= $p < 0.05$).

Figure 5. Mucosal CD8⁺ T-cell responses to S_{CoV-2} in mRNA-vaccinated mice which were further intranasally boosted with LV::S_{Beta-2P}. The mice are those detailed in the Figure 2. (A) Representative IFN-γ response by lung CD8⁺ T cells detected by intracellular cytokine staining after in vitro stimulation with a pool of S:256-275, S:536-550 and S:576-590 peptides. Cells are gated on alive CD45⁺ CD8⁺ T cells.

Figure 6

Figure 6. Lung T resident memory subset in mRNA-vaccinated mice which were further intranasally boosted with LV::S_{Beta-2P}. The mice are those detailed in the Figure 2. Mucosal immune cells were studied two weeks after LV::S_{Beta-2P} i.n. boost. (A) Cytometric gating strategy to detect lung CD8⁺ T resident memory (CD44⁺CD69⁺CD103⁺), and (B) percentages of this subset among CD8⁺ CD44⁺ T-cells in mRNA-vaccinated mice which were further intranasally boosted with LV::S_{Beta-2P}. Statistical significance was evaluated by Mann-Whitney test (*= *p* < 0.05).

Figure 7. Full protective capacity of LV::SBeta-2P i.n. boost against Delta variant in initially mRNA-primed and boosted mice. (A) Timeline of mRNA i.m.-i.m. prime-boost vaccination in C57BL/6 mice which were later immunized i.n. with 1×10^8 TU/mouse of LV::SBeta-2P ($n = 4-5$ /group), pre-treated i.n. with Ad5::hACE-2 4 days before i.n. challenge with 0.3×10^5 TCID₅₀ of SARS-CoV-2 Delta variant. **(B)** Comparative quantification of *hACE-2* mRNA in the lungs of Ad5::hACE-2 pre-treated mice at 3 dpi. **(C)** Lung viral RNA contents, evaluated by conventional E-specific (top) or sub-genomic Esg-specific (bottom) qRT-PCR at 3 dpi. Red lines indicate the detection limits. Statistical significance was evaluated by Mann-Whitney test (* = $p < 0.05$, ** = $p < 0.01$).